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Implementation of NK cell therapy is faced by several
obstacles: the small number of NK cells in peripheral
blood and the difficulties regarding production of effec-
tive cytolytic NK cells. We carried out this pilot study
to determine if NK cells could be expanded and their
degranulation, cytokines release abilities in response to
allogeneic tumor target by direct cytotoxitiy and by anti-
body-mediated cellular cytotoxicity can be achieved.
Methods
MNCs cells from healthy donors were stimulated with
K562. U293T cells were co-transduced with constructs
encoding the membrane-bound form of IL-15 and
human 4-1BBL. A 5-colour flow cytometry based esti-
mation of cytotoxicity (expression of CD107a, a surro-
gate marker for degranulation) and cytokine (IFN-g)
production was performed for both CD56brightCD16-
neg regulatory and CD56dimCD16pos cytolytic NK cell
subsets.
Results
Cell expansion of NK cell is feasible and both degranu-
lation and IFN-g release were specifically triggered by
cytolytic and regulatory NK cells against allogeneic
tumor cell line K562. Importantly, expanded NK cells
also mediated ADCC when cultured with PBMNCs in
the presence of serum bearing HLA-Class I and II
antibodies
Conclusion
Large number of cytolytic and regulatory NK cells can
be generated from MNCs in vitro suggesting the poten-
tial use of NK cell-based immunotherapy in tumors.
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